Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Heterogeneous to homogeneous melting transition visualized with ultrafast electron diffraction.

Mo MZ, Chen Z, Li RK, Dunning M, Witte BBL, Baldwin JK, Fletcher LB, Kim JB, Ng A, Redmer R, Reid AH, Shekhar P, Shen XZ, Shen M, Sokolowski-Tinten K, Tsui YY, Wang YQ, Zheng Q, Wang XJ, Glenzer SH.

Science. 2018 Jun 29;360(6396):1451-1455. doi: 10.1126/science.aar2058.

PMID:
29954977
2.

Nonequilibrium electron and lattice dynamics of strongly correlated Bi2Sr2CaCu2O8+δ single crystals.

Konstantinova T, Rameau JD, Reid AH, Abdurazakov O, Wu L, Li R, Shen X, Gu G, Huang Y, Rettig L, Avigo I, Ligges M, Freericks JK, Kemper AF, Dürr HA, Bovensiepen U, Johnson PD, Wang X, Zhu Y.

Sci Adv. 2018 Apr 27;4(4):eaap7427. doi: 10.1126/sciadv.aap7427. eCollection 2018 Apr.

3.

Publisher Correction: Beyond a phenomenological description of magnetostriction.

Reid AH, Shen X, Maldonado P, Chase T, Jal E, Granitzka PW, Carva K, Li RK, Li J, Wu L, Vecchione T, Liu T, Chen Z, Higley DJ, Hartmann N, Coffee R, Wu J, Dakowski GL, Schlotter WF, Ohldag H, Takahashi YK, Mehta V, Hellwig O, Fry A, Zhu Y, Cao J, Fullerton EE, Stöhr J, Oppeneer PM, Wang XJ, Dürr HA.

Nat Commun. 2018 Mar 7;9(1):1035. doi: 10.1038/s41467-018-03389-4.

4.

Beyond a phenomenological description of magnetostriction.

Reid AH, Shen X, Maldonado P, Chase T, Jal E, Granitzka PW, Carva K, Li RK, Li J, Wu L, Vecchione T, Liu T, Chen Z, Higley DJ, Hartmann N, Coffee R, Wu J, Dakovski GL, Schlotter WF, Ohldag H, Takahashi YK, Mehta V, Hellwig O, Fry A, Zhu Y, Cao J, Fullerton EE, Stöhr J, Oppeneer PM, Wang XJ, Dürr HA.

Nat Commun. 2018 Jan 26;9(1):388. doi: 10.1038/s41467-017-02730-7. Erratum in: Nat Commun. 2018 Mar 7;9(1):1035.

5.

Nanosecond X-Ray Photon Correlation Spectroscopy on Magnetic Skyrmions.

Seaberg MH, Holladay B, Lee JCT, Sikorski M, Reid AH, Montoya SA, Dakovski GL, Koralek JD, Coslovich G, Moeller S, Schlotter WF, Streubel R, Kevan SD, Fischer P, Fullerton EE, Turner JL, Decker FJ, Sinha SK, Roy S, Turner JJ.

Phys Rev Lett. 2017 Aug 11;119(6):067403. doi: 10.1103/PhysRevLett.119.067403. Epub 2017 Aug 9.

6.

Femtosecond mega-electron-volt electron microdiffraction.

Shen X, Li RK, Lundström U, Lane TJ, Reid AH, Weathersby SP, Wang XJ.

Ultramicroscopy. 2018 Jan;184(Pt A):172-176. doi: 10.1016/j.ultramic.2017.08.019. Epub 2017 Sep 1.

PMID:
28915441
7.

Electron-lattice energy relaxation in laser-excited thin-film Au-insulator heterostructures studied by ultrafast MeV electron diffraction.

Sokolowski-Tinten K, Shen X, Zheng Q, Chase T, Coffee R, Jerman M, Li RK, Ligges M, Makasyuk I, Mo M, Reid AH, Rethfeld B, Vecchione T, Weathersby SP, Dürr HA, Wang XJ.

Struct Dyn. 2017 Jul 21;4(5):054501. doi: 10.1063/1.4995258. eCollection 2017 Sep.

8.

Stacking order dynamics in the quasi-two-dimensional dichalcogenide 1T-TaS2 probed with MeV ultrafast electron diffraction.

Le Guyader L, Chase T, Reid AH, Li RK, Svetin D, Shen X, Vecchione T, Wang XJ, Mihailovic D, Dürr HA.

Struct Dyn. 2017 May 3;4(4):044020. doi: 10.1063/1.4982918. eCollection 2017 Jul.

9.

Magnetic Switching in Granular FePt Layers Promoted by Near-Field Laser Enhancement.

Granitzka PW, Jal E, Le Guyader L, Savoini M, Higley DJ, Liu T, Chen Z, Chase T, Ohldag H, Dakovski GL, Schlotter WF, Carron S, Hoffman MC, Gray AX, Shafer P, Arenholz E, Hellwig O, Mehta V, Takahashi YK, Wang J, Fullerton EE, Stöhr J, Reid AH, Dürr HA.

Nano Lett. 2017 Apr 12;17(4):2426-2432. doi: 10.1021/acs.nanolett.7b00052. Epub 2017 Mar 17.

10.

Single-shot mega-electronvolt ultrafast electron diffraction for structure dynamic studies of warm dense matter.

Mo MZ, Shen X, Chen Z, Li RK, Dunning M, Sokolowski-Tinten K, Zheng Q, Weathersby SP, Reid AH, Coffee R, Makasyuk I, Edstrom S, McCormick D, Jobe K, Hast C, Glenzer SH, Wang X.

Rev Sci Instrum. 2016 Nov;87(11):11D810.

PMID:
27910490
11.

Femtosecond X-ray magnetic circular dichroism absorption spectroscopy at an X-ray free electron laser.

Higley DJ, Hirsch K, Dakovski GL, Jal E, Yuan E, Liu T, Lutman AA, MacArthur JP, Arenholz E, Chen Z, Coslovich G, Denes P, Granitzka PW, Hart P, Hoffmann MC, Joseph J, Le Guyader L, Mitra A, Moeller S, Ohldag H, Seaberg M, Shafer P, Stöhr J, Tsukamoto A, Nuhn HD, Reid AH, Dürr HA, Schlotter WF.

Rev Sci Instrum. 2016 Mar;87(3):033110. doi: 10.1063/1.4944410.

PMID:
27036761
12.

Correlation-Driven Insulator-Metal Transition in Near-Ideal Vanadium Dioxide Films.

Gray AX, Jeong J, Aetukuri NP, Granitzka P, Chen Z, Kukreja R, Higley D, Chase T, Reid AH, Ohldag H, Marcus MA, Scholl A, Young AT, Doran A, Jenkins CA, Shafer P, Arenholz E, Samant MG, Parkin SS, Dürr HA.

Phys Rev Lett. 2016 Mar 18;116(11):116403. doi: 10.1103/PhysRevLett.116.116403. Epub 2016 Mar 18.

13.

Corrigendum: Indirect excitation of ultrafast demagnetization.

Vodungbo B, Tudu B, Perron J, Delaunay R, Müller L, Berntsen MH, Grübel G, Malinowski G, Weier C, Gautier J, Lambert G, Zeitoun P, Gutt C, Jal E, Reid AH, Granitzka PW, Jaouen N, Dakovski GL, Moeller S, Minitti MP, Mitra A, Carron S, Pfau B, von Korff Schmising C, Schneider M, Eisebitt S, Lüning J.

Sci Rep. 2016 Mar 4;6:21727. doi: 10.1038/srep21727. No abstract available.

14.

Climate confusion among U.S. teachers.

Plutzer E, McCaffrey M, Hannah AL, Rosenau J, Berbeco M, Reid AH.

Science. 2016 Feb 12;351(6274):664-5. doi: 10.1126/science.aab3907. No abstract available.

PMID:
26912845
15.

Indirect excitation of ultrafast demagnetization.

Vodungbo B, Tudu B, Perron J, Delaunay R, Müller L, Berntsen MH, Grübel G, Malinowski G, Weier C, Gautier J, Lambert G, Zeitoun P, Gutt C, Jal E, Reid AH, Granitzka PW, Jaouen N, Dakovski GL, Moeller S, Minitti MP, Mitra A, Carron S, Pfau B, von Korff Schmising C, Schneider M, Eisebitt S, Lüning J.

Sci Rep. 2016 Jan 6;6:18970. doi: 10.1038/srep18970. Erratum in: Sci Rep. 2016;6:21727. Tudu, Bahrati [corrected to Tudu, Bharati].

16.

Dynamic Structural Response and Deformations of Monolayer MoS2 Visualized by Femtosecond Electron Diffraction.

Mannebach EM, Li R, Duerloo KA, Nyby C, Zalden P, Vecchione T, Ernst F, Reid AH, Chase T, Shen X, Weathersby S, Hast C, Hettel R, Coffee R, Hartmann N, Fry AR, Yu Y, Cao L, Heinz TF, Reed EJ, Dürr HA, Wang X, Lindenberg AM.

Nano Lett. 2015 Oct 14;15(10):6889-95. doi: 10.1021/acs.nanolett.5b02805. Epub 2015 Sep 8.

PMID:
26322659
17.

Nanoscale Confinement of All-Optical Magnetic Switching in TbFeCo--Competition with Nanoscale Heterogeneity.

Liu TM, Wang T, Reid AH, Savoini M, Wu X, Koene B, Granitzka P, Graves CE, Higley DJ, Chen Z, Razinskas G, Hantschmann M, Scherz A, Stöhr J, Tsukamoto A, Hecht B, Kimel AV, Kirilyuk A, Rasing T, Dürr HA.

Nano Lett. 2015 Oct 14;15(10):6862-8. doi: 10.1021/acs.nanolett.5b02743. Epub 2015 Sep 1.

PMID:
26312732
18.

Mega-electron-volt ultrafast electron diffraction at SLAC National Accelerator Laboratory.

Weathersby SP, Brown G, Centurion M, Chase TF, Coffee R, Corbett J, Eichner JP, Frisch JC, Fry AR, Gühr M, Hartmann N, Hast C, Hettel R, Jobe RK, Jongewaard EN, Lewandowski JR, Li RK, Lindenberg AM, Makasyuk I, May JE, McCormick D, Nguyen MN, Reid AH, Shen X, Sokolowski-Tinten K, Vecchione T, Vetter SL, Wu J, Yang J, Dürr HA, Wang XJ.

Rev Sci Instrum. 2015 Jul;86(7):073702. doi: 10.1063/1.4926994.

19.

Reply to Wilson et al.

Viboud C, Eisenstein J, Reid AH, Janczewski TA, Morens DM, Taubenberger JK.

J Infect Dis. 2014 Sep 15;210(6):995-7. doi: 10.1093/infdis/jiu192. Epub 2014 Mar 27. No abstract available.

20.

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer.

Pezaro C, Mukherji D, Tunariu N, Cassidy AM, Omlin A, Bianchini D, Seed G, Reid AH, Olmos D, de Bono JS, Attard G.

Br J Cancer. 2013 Jul 23;109(2):325-31. doi: 10.1038/bjc.2013.340. Epub 2013 Jun 27.

21.

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.

Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, Reid AH, Attard G, Chen L, Kozarewa I, Gevensleben H, Campbell J, Fenwick K, Assiotis I, Olmos D, Yap TA, Fong P, Tunariu N, Koh D, Molife LR, Kaye S, Lord CJ, Ashworth A, de Bono J.

Ann Oncol. 2013 May;24(5):1416-8. doi: 10.1093/annonc/mdt074. Epub 2013 Mar 22. No abstract available.

PMID:
23524863
22.

Nanoscale spin reversal by non-local angular momentum transfer following ultrafast laser excitation in ferrimagnetic GdFeCo.

Graves CE, Reid AH, Wang T, Wu B, de Jong S, Vahaplar K, Radu I, Bernstein DP, Messerschmidt M, Müller L, Coffee R, Bionta M, Epp SW, Hartmann R, Kimmel N, Hauser G, Hartmann A, Holl P, Gorke H, Mentink JH, Tsukamoto A, Fognini A, Turner JJ, Schlotter WF, Rolles D, Soltau H, Strüder L, Acremann Y, Kimel AV, Kirilyuk A, Rasing T, Stöhr J, Scherz AO, Dürr HA.

Nat Mater. 2013 Apr;12(4):293-8. doi: 10.1038/nmat3597. Epub 2013 Mar 17.

PMID:
23503010
23.

Age- and sex-specific mortality associated with the 1918-1919 influenza pandemic in Kentucky.

Viboud C, Eisenstein J, Reid AH, Janczewski TA, Morens DM, Taubenberger JK.

J Infect Dis. 2013 Mar 1;207(5):721-9. doi: 10.1093/infdis/jis745. Epub 2012 Dec 10.

24.

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.

Olmos D, Brewer D, Clark J, Danila DC, Parker C, Attard G, Fleisher M, Reid AH, Castro E, Sandhu SK, Barwell L, Oommen NB, Carreira S, Drake CG, Jones R, Cooper CS, Scher HI, de Bono JS.

Lancet Oncol. 2012 Nov;13(11):1114-24. doi: 10.1016/S1470-2045(12)70372-8. Epub 2012 Oct 9.

25.

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, Thompson E, Hunt J, Sheridan E, Baikady B, Sarvadikar A, Maier G, Reid AH, Mulick Cassidy A, Olmos D, Attard G, de Bono J.

Ann Oncol. 2012 Nov;23(11):2943-7. doi: 10.1093/annonc/mds119. Epub 2012 Jul 5.

PMID:
22771826
26.

Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.

Reid AH, Attard G, Brewer D, Miranda S, Riisnaes R, Clark J, Hylands L, Merson S, Vergis R, Jameson C, Høyer S, Sørenson KD, Borre M, Jones C, de Bono JS, Cooper CS.

Mod Pathol. 2012 Jun;25(6):902-10. doi: 10.1038/modpathol.2011.207. Epub 2012 Mar 30.

27.

Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.

Attard G, Reid AH, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, Oommen NB, Folkerd E, Dowsett M, Arlt W, de Bono JS.

J Clin Endocrinol Metab. 2012 Feb;97(2):507-16. doi: 10.1210/jc.2011-2189. Epub 2011 Dec 14.

PMID:
22170708
28.

The CT flare response of metastatic bone disease in prostate cancer.

Messiou C, Cook G, Reid AH, Attard G, Dearnaley D, de Bono JS, de Souza NM.

Acta Radiol. 2011 Jun 1;52(5):557-61. doi: 10.1258/ar.2011.100342. Epub 2011 Mar 23.

PMID:
21498309
29.

Optical excitation of a forbidden magnetic resonance mode in a doped lutetium-iron-garnet film via the inverse Faraday effect.

Reid AH, Kimel AV, Kirilyuk A, Gregg JF, Rasing T.

Phys Rev Lett. 2010 Sep 3;105(10):107402. Epub 2010 Sep 3.

PMID:
20867547
30.

Abiraterone acetate is well tolerated without concomitant use of corticosteroids.

Attard G, Reid AH, de Bono JS.

J Clin Oncol. 2010 Oct 10;28(29):e560-1; author reply e562. doi: 10.1200/JCO.2010.29.5170. Epub 2010 Aug 30. No abstract available.

PMID:
20805462
31.

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.

Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, Arkenau HT, Karavasilis V, Yap TA, Olmos D, Spicer J, Postel-Vinay S, Yin D, Lipton A, Demers L, Leitzel K, Gualberto A, de Bono JS.

Br J Cancer. 2010 Jul 27;103(3):332-9. doi: 10.1038/sj.bjc.6605767. Epub 2010 Jul 13.

32.

Integrated biology and undergraduate science education: a new biology education for the twenty-first century?

Labov JB, Reid AH, Yamamoto KR.

CBE Life Sci Educ. 2010 Spring;9(1):10-6. doi: 10.1187/cbe.09-12-0092. No abstract available.

33.

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.

Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS.

J Clin Oncol. 2010 Mar 20;28(9):1489-95. doi: 10.1200/JCO.2009.24.6819. Epub 2010 Feb 16.

34.

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.

Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Møller H, Reuter VE, Scardino PT, Cuzick J, de Bono JS, Cooper CS; Transatlantic Prostate Group.

Br J Cancer. 2010 Feb 16;102(4):678-84. doi: 10.1038/sj.bjc.6605554. Epub 2010 Jan 26.

35.

A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors.

Reid AH, Protheroe A, Attard G, Hayward N, Vidal L, Spicer J, Shaw HM, Bone EA, Carter J, Hooftman L, Harris A, De Bono JS.

Clin Cancer Res. 2009 Aug 1;15(15):4978-85. doi: 10.1158/1078-0432.CCR-09-0306. Epub 2009 Jul 28.

36.

Targeting the PI3K/AKT pathway for the treatment of prostate cancer.

Sarker D, Reid AH, Yap TA, de Bono JS.

Clin Cancer Res. 2009 Aug 1;15(15):4799-805. doi: 10.1158/1078-0432.CCR-08-0125. Epub 2009 Jul 28. Review.

37.

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).

Molife LR, Attard G, Fong PC, Karavasilis V, Reid AH, Patterson S, Riggs CE Jr, Higano C, Stadler WM, McCulloch W, Dearnaley D, Parker C, de Bono JS.

Ann Oncol. 2010 Jan;21(1):109-13. doi: 10.1093/annonc/mdp270. Epub 2009 Jul 16.

PMID:
19608618
38.

A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies.

Attard G, Rizzo S, Ledaki I, Clark J, Reid AH, Thompson A, Khoo V, de Bono JS, Cooper CS, Hudson DL.

Prostate. 2009 Oct 1;69(14):1507-20. doi: 10.1002/pros.20997.

PMID:
19544327
39.

Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

Attard G, Reid AH, Olmos D, de Bono JS.

Cancer Res. 2009 Jun 15;69(12):4937-40. doi: 10.1158/0008-5472.CAN-08-4531. Epub 2009 Jun 9. Review.

40.

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS.

J Clin Oncol. 2009 Aug 10;27(23):3742-8. doi: 10.1200/JCO.2008.20.0642. Epub 2009 May 26.

41.

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS.

Cancer Res. 2009 Apr 1;69(7):2912-8. doi: 10.1158/0008-5472.CAN-08-3667.

42.

CYP17 inhibition as a hormonal strategy for prostate cancer.

Reid AH, Attard G, Barrie E, de Bono JS.

Nat Clin Pract Urol. 2008 Nov;5(11):610-20. doi: 10.1038/ncpuro1237. Review.

PMID:
18985049
43.

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.

Olmos D, Arkenau HT, Ang JE, Ledaki I, Attard G, Carden CP, Reid AH, A'Hern R, Fong PC, Oomen NB, Molife R, Dearnaley D, Parker C, Terstappen LW, de Bono JS.

Ann Oncol. 2009 Jan;20(1):27-33. doi: 10.1093/annonc/mdn544. Epub 2008 Aug 11.

PMID:
18695026
44.

New prostate cancer drug: Prostate cancer's day in the sun.

Attard G, Reid AH, Dearnaley D, De Bono JS.

BMJ. 2008 Aug 11;337:a1249. doi: 10.1136/bmj.a1249. No abstract available.

PMID:
18694888
45.

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS.

J Clin Oncol. 2008 Oct 1;26(28):4563-71. doi: 10.1200/JCO.2007.15.9749. Epub 2008 Jul 21. Erratum in: J Clin Oncol. 2012 May 20;30(15):1896.

PMID:
18645193
46.

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.

Blagden SP, Molife LR, Seebaran A, Payne M, Reid AH, Protheroe AS, Vasist LS, Williams DD, Bowen C, Kathman SJ, Hodge JP, Dar MM, de Bono JS, Middleton MR.

Br J Cancer. 2008 Mar 11;98(5):894-9. doi: 10.1038/sj.bjc.6604264. Epub 2008 Mar 4.

47.

Metagenomics: a call for bringing a new science into the classroom (while it's still new).

Jurkowski A, Reid AH, Labov JB.

CBE Life Sci Educ. 2007 Winter;6(4):260-5. No abstract available.

48.

Characterization of the 1918 influenza virus polymerase genes.

Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG.

Nature. 2005 Oct 6;437(7060):889-93.

PMID:
16208372
49.

Evaluation of PCR testing of ethanol-fixed nasal swab specimens as an augmented surveillance strategy for influenza virus and adenovirus identification.

Krafft AE, Russell KL, Hawksworth AW, McCall S, Irvine M, Daum LT, Connoly JL, Reid AH, Gaydos JC, Taubenberger JK.

J Clin Microbiol. 2005 Apr;43(4):1768-75.

50.

Capturing a killer flu virus.

Taubenberger JK, Reid AH, Fanning TG.

Sci Am. 2005 Jan;292(1):48-57. No abstract available.

PMID:
15724338

Supplemental Content

Support Center